The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:1269-1271 March 22, 2007 Number 12
NextNext

Peginterferon and Ribavirin for Hepatitis C

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Hoofnagle, J. H.
-PubMed Citation
To the Editor: In their review of peginterferon and ribavirin for the treatment of hepatitis C, Hoofnagle and Seeff (Dec. 7 issue)1 do not include data on the association between the consumption of alcohol and both treatment response and disease progression. Level-one evidence of the deleterious effects of alcohol on hepatitis C virus (HCV) RNA levels, on the response to treatment, and on disease progression led the National Institutes of Health and the American Gastroenterological Association to issue position statements advising that "abstinence should be recommended before and during antiviral treatment . . . [since] even moderate alcohol consumption can have a . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.